NanoString Technologies Inc (NSTGQ) Financial Statements (2026 and earlier)

Company Profile

Business Address 530 FAIRVIEW AVENUE NORTH
SEATTLE, WA 98109
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments117,602154,644196,532230,453272,342312,075
Cash and cash equivalent114,305121,408112,250117,069126,02798,457
Short-term investments3,29733,23684,282113,384146,315213,618
Restricted cash and investments625625898   
Receivables42,98234,86731,50627,27331,40430,381
Inventory, net of allowances, customer advances and progress billings48,84946,71143,27345,76141,52434,590
Inventory48,84946,71143,27345,76141,52434,590
Other undisclosed current assets11,38715,01114,56515,2219,42710,084
Total current assets:221,445251,858286,774318,708354,697387,130
Noncurrent Assets
Operating lease, right-of-use asset15,45816,48417,58118,58617,64518,562
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization47,93947,72944,45740,37435,41432,704
Other noncurrent assets4,1484,3444,6005,9325,6236,324
Total noncurrent assets:67,54568,55766,63864,89258,68257,590
TOTAL ASSETS:288,990320,415353,412383,600413,379444,720
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities29,51726,66724,50336,46037,02035,155
Employee-related liabilities✕✕✕✕14,73313,72912,188
Accounts payable20,86820,48616,61916,82916,29218,426
Accrued liabilities8,6496,1817,8844,8986,9994,541
Deferred revenue12,28711,6469,5888,0267,9878,053
Other undisclosed current liabilities20,62919,67824,7696,4536,8376,378
Total current liabilities:62,43357,99158,86050,93951,84449,586
Noncurrent Liabilities
Long-term debt and lease obligation, including:227,379227,001226,622226,250225,877225,511
Other undisclosed long-term debt and lease obligation227,379227,001226,622206,524206,741205,013
Liabilities, other than long-term debt20,63921,80322,1163,7573,8573,820
Deferred revenue4,8364,6003,7543,7573,8573,820
Operating lease, liability15,80317,20318,36219,72619,13620,498
Other undisclosed noncurrent liabilities    19,72619,13620,498
Total noncurrent liabilities:248,018248,804248,738249,733248,870249,829
Total liabilities:310,451306,795307,598300,672300,714299,415
Equity
Equity, attributable to parent(21,461)13,62045,81482,928112,665145,305
Common stock555555
Additional paid in capital872,732864,204855,694849,406842,602835,845
Accumulated other comprehensive income (loss)4(55)(589)(1,301)(1,450)(1,292)
Accumulated deficit(894,202)(850,534)(809,296)(765,182)(728,492)(689,253)
Total equity:(21,461)13,62045,81482,928112,665145,305
TOTAL LIABILITIES AND EQUITY:288,990320,415353,412383,600413,379444,720

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues44,15735,80534,42229,54132,21931,080
Cost of revenue(29,757)(22,871)(21,122)(13,723)(15,852)(14,778)
Gross profit:14,40012,93413,30015,81816,36716,302
Operating expenses(57,290)(53,484)(55,981)(50,759)(53,458)(53,772)
Operating loss:(42,890)(40,550)(42,681)(34,941)(37,091)(37,470)
Nonoperating expense(573)(613)(1,438)(1,692)(1,964)(1,949)
Investment income, nonoperating(362)(606) (1,113)(1,474)(1,732)
Other nonoperating expense(211)(7) (579)(490)(217)
Other undisclosed loss from continuing operations before equity method investments, income taxes   (7,500)   
Loss from continuing operations before equity method investments, income taxes:(43,463)(41,163)(51,619)(36,633)(39,055)(39,419)
Other undisclosed income from continuing operations before income taxes   7,500   
Loss from continuing operations before income taxes:(43,463)(41,163)(44,119)(36,633)(39,055)(39,419)
Income tax expense (benefit)(205)(75)5(57)(184)(81)
Loss from continuing operations:(43,668)(41,238)(44,114)(36,690)(39,239)(39,500)
Loss before gain (loss) on sale of properties:✕✕✕✕(36,690)(39,239)(39,500)
Net loss available to common stockholders, diluted:(43,668)(41,238)(44,114)(36,690)(39,239)(39,500)

Comprehensive Income ($ in thousands)
Annual | Quarterly

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(43,668)(41,238)(44,114)(36,690)(39,239)(39,500)
Other comprehensive income (loss) 59534 149(974)(974)
Other undisclosed comprehensive loss   (271)   
Comprehensive loss:(43,609)(40,704)(44,385)(36,541)(40,213)(40,474)
Other undisclosed comprehensive income, net of tax, attributable to parent   983 816 
Comprehensive loss, net of tax, attributable to parent:(43,609)(40,704)(43,402)(36,541)(39,397)(40,474)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: